Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2020.0409
Abstract: Importance Because of socioeconomic factors, many patients with advanced non-small cell lung cancer (NSCLC) do not receive immunotherapy in the first-line setting. It is unknown if the combination of immunotherapy with chemotherapy can provide clinical… read more here.
Keywords: pembrolizumab plus; advanced non; safety; plus docetaxel ... See more keywords
Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First‐Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung — A Multicenter, Open‐label, Randomized, Phase III Trial
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.07.006
Abstract: Introduction: This study aimed to compare the efficacy of first‐line nedaplatin (80 mg/m2) plus docetaxel (75 mg/m2) (ND) versus cisplatin (75 mg/m2) plus docetaxel (75 mg/m2) (CD) in patients with advanced squamous cell lung carcinoma.… read more here.
Keywords: first line; squamous cell; nedaplatin plus; plus docetaxel ... See more keywords
Re: Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma after Platinum-Based Therapy (RANGE): A Randomised, Double-Blind, Phase 3 Trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Urology"
DOI: 10.1097/01.ju.0000554640.11985.be
Abstract: available at http://www.ncbi.nlm.nih.gov/pubmed/28916371 Editorial Comment: Increasing attention has been placed on the treatment of advanced or metastatic urothelial carcinoma that has progressed during or after platinum based chemotherapy. Inroads have been made with immunotherapy options,… read more here.
Keywords: treatment; cancer; urothelial carcinoma; oncology ... See more keywords
Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatured gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4061
Abstract: 4061Background: This trial was a phase II study with selumetinib (AZD6244)/docetaxel as second-line treatment for metastatic GC patients with MEK signature or RAS gene alterations as part of the GC... read more here.
Keywords: selumetinib plus; trial; docetaxel second; plus docetaxel ... See more keywords
KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.10
Abstract: 10Background: For men with mCRPC, systemic therapies such as docetaxel and cabazitaxel improve survival, but more effective treatments are needed. KEYNOTE-365 (NCT02861573) is a phase 1b/2 study to... read more here.
Keywords: pembrolizumab pembro; 365 cohort; keynote 365; cohort pembrolizumab ... See more keywords
Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.922127
Abstract: Objective The aim of this study is to compare gemcitabine (G) plus docetaxel (D) versus G plus anlotinib (A) for advanced soft tissue sarcoma (STS). Methods We retrospectively investigated 122 patients with locally advanced or… read more here.
Keywords: gemcitabine plus; sarcoma; advanced soft; plus docetaxel ... See more keywords
Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
Sign Up to like & getrecommendations! Published in 2017 at "Oncology Letters"
DOI: 10.3892/ol.2017.6679
Abstract: In a Phase III trial for HER2-positive breast cancer (the CLEOPATRA study), the triple-drug combination arm of pertuzumab plus trastuzumab plus docetaxel showed significantly longer progression-free survival and overall survival than did the trastuzumab plus… read more here.
Keywords: combination; triple drug; trastuzumab plus; plus docetaxel ... See more keywords